(CI) Cigna - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US1255231003
Stock:
Total Rating 42
Risk 75
Buy Signal 0.12
| Risk 5d forecast | |
|---|---|
| Volatility | 32.2% |
| Relative Tail Risk | -20.4% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.03 |
| Alpha | -9.72 |
| Character TTM | |
|---|---|
| Beta | 0.197 |
| Beta Downside | 0.109 |
| Drawdowns 3y | |
|---|---|
| Max DD | 32.10% |
| CAGR/Max DD | 0.07 |
EPS (Earnings per Share)
Revenue
Description: CI Cigna
The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers. The company's Cigna Healthcare segment offers medical, pharmacy, behavioral health, dental, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as individual health insurance plans; and health care coverage in its international markets, as well as health care benefits for mobile individuals and employees of multinational organizations. In addition, it offers permanent insurance contracts sold to corporations to provide coverage on the lives of certain employees for financing employer-paid future benefit obligations and stop loss insurance. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was formerly known as Cigna Corporation and changed its name to The Cigna Group in February 2023. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: 5.96b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -0.43 > 1.0 |
| NWC/Revenue: -3.10% < 20% (prev -3.69%; Δ 0.58% < -1%) |
| CFO/TA 0.06 > 3% & CFO 9.60b > Net Income 5.96b |
| Net Debt (23.79b) to EBITDA (11.98b): 1.99 < 3 |
| Current Ratio: 0.85 > 1.5 & < 3 |
| Outstanding Shares: last quarter (265.9m) vs 12m ago -4.26% < -2% |
| Gross Margin: 9.45% > 18% (prev 0.11%; Δ 934.6% > 0.5%) |
| Asset Turnover: 175.2% > 50% (prev 158.5%; Δ 16.71% > 0%) |
| Interest Coverage Ratio: 6.77 > 6 (EBITDA TTM 11.98b / Interest Expense TTM 1.38b) |
Altman Z'' 1.44
| A: -0.05 (Total Current Assets 47.81b - Total Current Liabilities 56.34b) / Total Assets 157.92b |
| B: 0.30 (Retained Earnings 47.87b / Total Assets 157.92b) |
| C: 0.06 (EBIT TTM 9.35b / Avg Total Assets 156.90b) |
| D: 0.39 (Book Value of Equity 45.06b / Total Liabilities 116.05b) |
| Altman-Z'' Score: 1.44 = BB |
Beneish M -2.81
| DSRI: 1.07 (Receivables 28.77b/24.07b, Revenue 274.95b/247.12b) |
| GMI: 1.11 (GM 9.45% / 10.51%) |
| AQI: 0.99 (AQ_t 0.67 / AQ_t-1 0.68) |
| SGI: 1.11 (Revenue 274.95b / 247.12b) |
| TATA: -0.02 (NI 5.96b - CFO 9.60b) / TA 157.92b) |
| Beneish M-Score: -2.81 (Cap -4..+1) = A |
What is the price of CI shares?
As of March 01, 2026, the stock is trading at USD 289.82 with a total of 2,245,637 shares traded.
Over the past week, the price has changed by +3.39%, over one month by +7.30%, over three months by +5.11% and over the past year by -2.36%.
Over the past week, the price has changed by +3.39%, over one month by +7.30%, over three months by +5.11% and over the past year by -2.36%.
Is CI a buy, sell or hold?
Cigna has received a consensus analysts rating of 4.28.
Therefore, it is recommended to buy CI.
- StrongBuy: 13
- Buy: 6
- Hold: 6
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 332.6 | 14.8% |
| Analysts Target Price | 332.6 | 14.8% |
CI Fundamental Data Overview February 28, 2026
P/E Trailing = 13.0216
P/E Forward = 9.1408
P/S = 0.2807
P/B = 1.9713
P/EG = 0.5299
Revenue TTM = 274.95b USD
EBIT TTM = 9.35b USD
EBITDA TTM = 11.98b USD
Long Term Debt = 30.95b USD (from longTermDebt, two quarters ago)
Short Term Debt = 592.0m USD (from shortTermDebt, last quarter)
Debt = 31.46b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 23.79b USD (from netDebt column, last quarter)
Enterprise Value = 100.94b USD (77.15b + Debt 31.46b - CCE 7.68b)
Interest Coverage Ratio = 6.77 (Ebit TTM 9.35b / Interest Expense TTM 1.38b)
EV/FCF = 12.03x (Enterprise Value 100.94b / FCF TTM 8.39b)
FCF Yield = 8.31% (FCF TTM 8.39b / Enterprise Value 100.94b)
FCF Margin = 3.05% (FCF TTM 8.39b / Revenue TTM 274.95b)
Net Margin = 2.17% (Net Income TTM 5.96b / Revenue TTM 274.95b)
Gross Margin = 9.45% ((Revenue TTM 274.95b - Cost of Revenue TTM 248.97b) / Revenue TTM)
Gross Margin QoQ = 7.66% (prev 8.52%)
Tobins Q-Ratio = 0.64 (Enterprise Value 100.94b / Total Assets 157.92b)
Interest Expense / Debt = 1.06% (Interest Expense 335.0m / Debt 31.46b)
Taxrate = 24.25% (395.0m / 1.63b)
NOPAT = 7.08b (EBIT 9.35b * (1 - 24.25%))
Current Ratio = 0.85 (Total Current Assets 47.81b / Total Current Liabilities 56.34b)
Debt / Equity = 0.75 (Debt 31.46b / totalStockholderEquity, last quarter 41.71b)
Debt / EBITDA = 1.99 (Net Debt 23.79b / EBITDA 11.98b)
Debt / FCF = 2.84 (Net Debt 23.79b / FCF TTM 8.39b)
Total Stockholder Equity = 40.99b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.80% (Net Income 5.96b / Total Assets 157.92b)
RoE = 14.53% (Net Income TTM 5.96b / Total Stockholder Equity 40.99b)
RoCE = 13.00% (EBIT 9.35b / Capital Employed (Equity 40.99b + L.T.Debt 30.95b))
RoIC = 9.77% (NOPAT 7.08b / Invested Capital 72.50b)
WACC = 4.95% (E(77.15b)/V(108.61b) * Re(6.64%) + D(31.46b)/V(108.61b) * Rd(1.06%) * (1-Tc(0.24)))
Discount Rate = 6.64% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -4.98%
[DCF] Terminal Value 86.08% ; FCFF base≈8.62b ; Y1≈8.40b ; Y5≈8.45b
[DCF] Fair Price = 869.6 (EV 252.90b - Net Debt 23.79b = Equity 229.12b / Shares 263.5m; r=5.90% [WACC]; 5y FCF grow -3.56% → 2.90% )
EPS Correlation: 78.55 | EPS CAGR: 8.21% | SUE: 0.35 | # QB: 0
Revenue Correlation: 97.74 | Revenue CAGR: 14.23% | SUE: 3.48 | # QB: 12
EPS next Quarter (2026-03-31): EPS=7.63 | Chg7d=+0.044 | Chg30d=+0.386 | Revisions Net=+12 | Analysts=19
EPS current Year (2026-12-31): EPS=30.31 | Chg7d=+0.005 | Chg30d=-0.152 | Revisions Net=-2 | Growth EPS=+1.6% | Growth Revenue=+2.3%
EPS next Year (2027-12-31): EPS=33.47 | Chg7d=-0.023 | Chg30d=-0.033 | Revisions Net=-5 | Growth EPS=+10.4% | Growth Revenue=+5.8%
[Analyst] Revisions Ratio: +0.86 (13 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 0.3% (Discount Rate 7.9% - Earnings Yield 7.7%)
[Growth] Growth Spread = +1.0% (Analyst 1.3% - Implied 0.3%)
P/E Forward = 9.1408
P/S = 0.2807
P/B = 1.9713
P/EG = 0.5299
Revenue TTM = 274.95b USD
EBIT TTM = 9.35b USD
EBITDA TTM = 11.98b USD
Long Term Debt = 30.95b USD (from longTermDebt, two quarters ago)
Short Term Debt = 592.0m USD (from shortTermDebt, last quarter)
Debt = 31.46b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 23.79b USD (from netDebt column, last quarter)
Enterprise Value = 100.94b USD (77.15b + Debt 31.46b - CCE 7.68b)
Interest Coverage Ratio = 6.77 (Ebit TTM 9.35b / Interest Expense TTM 1.38b)
EV/FCF = 12.03x (Enterprise Value 100.94b / FCF TTM 8.39b)
FCF Yield = 8.31% (FCF TTM 8.39b / Enterprise Value 100.94b)
FCF Margin = 3.05% (FCF TTM 8.39b / Revenue TTM 274.95b)
Net Margin = 2.17% (Net Income TTM 5.96b / Revenue TTM 274.95b)
Gross Margin = 9.45% ((Revenue TTM 274.95b - Cost of Revenue TTM 248.97b) / Revenue TTM)
Gross Margin QoQ = 7.66% (prev 8.52%)
Tobins Q-Ratio = 0.64 (Enterprise Value 100.94b / Total Assets 157.92b)
Interest Expense / Debt = 1.06% (Interest Expense 335.0m / Debt 31.46b)
Taxrate = 24.25% (395.0m / 1.63b)
NOPAT = 7.08b (EBIT 9.35b * (1 - 24.25%))
Current Ratio = 0.85 (Total Current Assets 47.81b / Total Current Liabilities 56.34b)
Debt / Equity = 0.75 (Debt 31.46b / totalStockholderEquity, last quarter 41.71b)
Debt / EBITDA = 1.99 (Net Debt 23.79b / EBITDA 11.98b)
Debt / FCF = 2.84 (Net Debt 23.79b / FCF TTM 8.39b)
Total Stockholder Equity = 40.99b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.80% (Net Income 5.96b / Total Assets 157.92b)
RoE = 14.53% (Net Income TTM 5.96b / Total Stockholder Equity 40.99b)
RoCE = 13.00% (EBIT 9.35b / Capital Employed (Equity 40.99b + L.T.Debt 30.95b))
RoIC = 9.77% (NOPAT 7.08b / Invested Capital 72.50b)
WACC = 4.95% (E(77.15b)/V(108.61b) * Re(6.64%) + D(31.46b)/V(108.61b) * Rd(1.06%) * (1-Tc(0.24)))
Discount Rate = 6.64% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -4.98%
[DCF] Terminal Value 86.08% ; FCFF base≈8.62b ; Y1≈8.40b ; Y5≈8.45b
[DCF] Fair Price = 869.6 (EV 252.90b - Net Debt 23.79b = Equity 229.12b / Shares 263.5m; r=5.90% [WACC]; 5y FCF grow -3.56% → 2.90% )
EPS Correlation: 78.55 | EPS CAGR: 8.21% | SUE: 0.35 | # QB: 0
Revenue Correlation: 97.74 | Revenue CAGR: 14.23% | SUE: 3.48 | # QB: 12
EPS next Quarter (2026-03-31): EPS=7.63 | Chg7d=+0.044 | Chg30d=+0.386 | Revisions Net=+12 | Analysts=19
EPS current Year (2026-12-31): EPS=30.31 | Chg7d=+0.005 | Chg30d=-0.152 | Revisions Net=-2 | Growth EPS=+1.6% | Growth Revenue=+2.3%
EPS next Year (2027-12-31): EPS=33.47 | Chg7d=-0.023 | Chg30d=-0.033 | Revisions Net=-5 | Growth EPS=+10.4% | Growth Revenue=+5.8%
[Analyst] Revisions Ratio: +0.86 (13 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 0.3% (Discount Rate 7.9% - Earnings Yield 7.7%)
[Growth] Growth Spread = +1.0% (Analyst 1.3% - Implied 0.3%)